ZNF677 and neoplasm: We found tumor-specific ZNF677 downregulation in “breast invasive carcinoma” (p = 8.2 * 10−46), “colon and rectum adenocarcinoma” (p = 1.5 * 10−7), “kidney renal clear cell carcinoma” (p = 1 * 10−20), “head and neck squamous cell carcinoma” (p = 1 * 10−11) and “uterine corpus endometrioid carcinoma” (p = 0.001) patients (supplementary Figure S1).